ErbB-3 based methods and compositions for treating neoplasms
The present invention relates to compositions and methods for treating neoplasms in mammals, particularly humans. More particularly, the present invention provides for methods for preventing, treating or delaying neoplasm in a mammal using an ErbB-3 protein, a nucleic acid encoding an ErbB-3 protein or a functional fragment thereof. The present invention also provides for isolated nucleic acids encoding an extracellular domain of the ErbB-3 protein, or a functional fragment thereof, substantially purified extracellular domain of the ErbB-3 protein, or a functional fragment thereof and antibodies that bind to an epitope in an extracellular domain of the ErbB-3 protein, or a functional fragment thereof. The present invention further provides for pharmaceutical compositions and/or vaccines comprising the extracellular domain of the ErbB-3 protein, or a functional fragment thereof, or nucleic acids encoding and antibodies binding to such extracellular domain or functional fragments thereof.
1. A method for treating a neoplasm which expresses ErbB-3 in a mammal, which method comprises administering to a mammal, to which such treatment is needed or desirable, an effective amount of an ErbB-3 protein or a nucleic acid that encodes and expresses said ErbB-3 protein, whereby an immune response is generated against said neoplasm, wherein the ErbB-3 protein is a fragment of the extracellular domain of ErbB3 and comprises:
(a) the amino acid sequence set forth in SEQ ID NO:3; or
(b) amino acid residues 24-81 of the amino acid sequence set forth in SEQ ID NO:14; or
(c) amino acid residues 2-139 of the amino acid sequence set forth in SEQ ID NO:16,
wherein the ErbB-3 protein is not the entire extracellular domain of ErbB3.
2. The method of claim 1 , further comprising administering an immune response potentiator to the mammal.
3. The method of claim 1 , wherein the ErbB-3 protein or the nucleic acid that encodes and expresses said ErbB-3 protein is co-administered with a pharmaceutically acceptable carrier or excipient.
4. The method of claim 1 , wherein the ErbB-3 protein or the nucleic acid that encodes and expresses said ErbB-3 protein is co-administered with an anti-neoplasm agent.
5. The method of claim 4 , wherein the anti-neoplasm agent is selected from the group consisting of an anti-angiogenic agent, an alkylating agent, an antimetabolite, a natural product, a platinum coordination complex, an anthracenedione, a substituted urea, a methylhydrazine derivative, an adrenocortical suppressant, a hormone, an antagonist, an oncogene inhibitor, a tumor suppressor gene or protein, an anti-oncogene antibody and an anti-oncogene antisense oligonucleotide.
6. The method of claim 1 , wherein the neoplasm to be treated is selected from the group consisting of adrenal gland, anus, auditory nerve, bile ducts, bladder, bone, brain, breast, bruccal, central nervous system, cervix, colon, ear, endometrium, esophagus, eye, eyelids, fallopian tube, gastrointestinal tract, head and neck, heart, kidney, larynx, liver, lung, mandible, mandibular condyle, maxilla, mouth, nasopharynx, nose, oral cavity, ovary, pancreas, parotid gland, penis, pinna, pituitary, prostate gland, rectum, retina, salivary glands, skin, small intestine, spinal cord, stomach, testes, thyroid, tonsil, urethra, uterus, vagina, vestibulocochlear nerve and vulva neoplasm.
7. The method of claim 1 , wherein the neoplasm to be treated is selected from the group consisting of breast, ovary, stomach, prostate, colon and lung cancer.
8. The method of claim 1 , wherein the neoplasm to be treated is breast cancer.
9. The method of claim 1 , wherein the mammal is a human.
10. The method of claim 9 , wherein the administering is by subcutaneous injection.
11. The method of claim 1 , wherein the administering is by intracavernous injection, subcutaneous injection, intravenous injection, intramuscular injection, intradermal injection, oral administration or topical administration.
12. The method of claim 1 , wherein the ErbB-3 protein is administered to the neoplasm in situ.
13. The method of claim 12 , further comprising administering an immune response potentiator to the neoplasm in situ.